''One size fits all'' unique drug to eradicate multiple viral species simultaneously from the central nervous system of co-infected individuals

Informations projet

NOVIRUSES2BRAIN

N° de convention de subvention: 828774

DOI

10.3030/828774

Projet clôturé

Date de signature de la CE 17 Decembre 2018

Date de début 1 Septembre 2019

Date de fin 31 Août 2025

Financé au titre de

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Coût total

€ 3 933 965,63

Contribution de l’UE

€ 3 933 965,63

Coordonné par

FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE
Portugal

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Open Research Data Pilot (1)

Data Management Plan

"A Data Management Plan (DMP) will be elaborated including what data the project will generate, whether and how it will be made accessible for verification and re-use, and how it will be curated and preserved. Through this DMP the Consortium can define certain datasets to remain closed according to the principle ""as open as possible, as closed as necessary""."

Websites, patent fillings, videos etc. (1)

Website and project logo

Dedicated website will be launched and a project logo, as the first communication package of the project.

Documents, reports (2)

First technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Second technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Publications

Peer reviewed articles (5)

A designed cyclic analogue of gomesin has potent activity against Staphylococcus aureus biofilms

Auteurs: Dias, Susana Pinto, Sandra Silva-Herdade, Ana S. Cheneval, Olivier Craik, David J Coutinho, Ana Castanho, Miguel A. R. B. Henriques, Sónia T. Veiga, Ana Salomé
Publié dans: J Antimicrob Chemother., 2022, ISSN 0305-7453
Éditeur: Oxford University Press
DOI: 10.1093/jac/dkac309

Penetrating the Blood-Brain Barrier with New Peptide-Porphyrin Conjugates Having anti-HIV Activity.

Auteurs: Mendonça, Diogo A. Bakker, Mariët Cruz-Oliveira, Christine Neves, Vera Angeles Jiménez, Maria Defaus, Sira Cavaco, Marco Veiga, Ana Salomé Cadima Couto, Carla Iris Castanho, Miguel A. R. B. Andreu, David Todorovski, Toni
Publié dans: Bioconjugate Chem., 2021, ISSN 1043-1802
Éditeur: American Chemical Society
DOI: 10.1021/acs.bioconjchem.1c00123

Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide–Porphyrin Conjugates

Auteurs: Toni Todorovski ,Diogo A. Mendonça ,Lorena O. Fernandes-Siqueira, Christine Cruz-Oliveira ,Giuseppina Guida 1,Javier Valle 1,Marco Cavaco 2ORCID,Fernanda I. V. Limas 3,Vera Neves 2ORCID,Íris Cadima-Couto 2,Sira Defaus 1,Ana Salomé Veiga 2,Andrea T. Da Poian 3,Miguel A. R. B. Castanho 2 and David Andreu
Publié dans: Pharmaceutics, 2022, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14040738

Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives

Auteurs: David Andreu; Daniela Kalafatovic; Toni Todorovski
Publié dans: Pharmaceutics, 2023, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15020357

Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope

Auteurs: Diogo A. Mendonça, Iris Cadima-Couto, Carolina C. Buga, Zoe A. Arnaut, Fabio A. Schaberle, Luis G. Arnaut, Miguel A.R.B. Castanho, Christine Cruz-Oliveira
Publié dans: Biomedicine & Pharmacotherapy, Numéro 176, 2024, Page(s) 116768, ISSN 0753-3322
Éditeur: Elsevier Masson
DOI: 10.1016/j.biopha.2024.116768